• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Societal CDMO

    CMC Pharmaceuticals

    Vector Partners Limited

    Quotient Sciences

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Societal CDMO

    CMC Pharmaceuticals

    Vector Partners Limited

    Quotient Sciences

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biosimilars Outsourcing and Capacity

    CMOs to play important but uncertain role in biosimilars manufacturing

    Biosimilars Outsourcing and Capacity
    Biosimilars Outsourcing and Capacity
    Related CONTENT
    • Lakes BioScience Signs Agreement with Cytvia
    • Lonza Appoints Philippe Deecke as CFO
    • Stelis Biopharma Appoints Mark Womack as CEO
    • Pfizer's 2Q Revenues Up 92%
    • Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up
    Ronald A. Rader and Eric S. Langer, BioPlan Associates05.05.16
    Biosimilars are unlikely to be manufactured by conventional bioprocessing strategies—those used by biopharma companies and contract manufacturing organizations (CMOs) over the past 20-plus years. Rather, a number of alternative paths to traditional CMO, and in-house bioprocessing are already emerging.

    There are many regional manufacturers, not only in major markets, but in emerging areas where an increasing number of companies are getting involved with biosimilars, both developers and CMOs. While in the past, many generally had no experience in cGMP production, this, too, is changing. More partnerships among regional biopharma companies and biosimilars developers and CMOs are also being formed. 

    So it is unlikely that the biosimilars industry today, will resemble the segment in five or 10 years. CMOs are likely to play an important role, yet it may not necessarily be the leading CMOs today that create success or get most of the biosimilars business. CMOs with excellent bioprocessing expertise and process development competence may not necessarily be attracted by the lower margins associated with biosimilars, nor will they be as cost competitive compared with more nimble CMOs that have the needed GMP expertise.

    Biosimilars current events
    Much has happened during the past year in biosimilars.1 We now have the first two biosimilar products in the U.S.—Zarxio from Sandoz/Novartis, and Inflectra, a monoclonal antibody (mAb) from Janssen Biotech/Johnson & Johnson.  These were approved by FDA with no apparent significant problems. Inflectra is the first approval of a biosimilar mAb, a class of products only a few years ago presumed by many to likely require substantial FDA biosimilars regulation before gaining sufficient confidence to grant approvals. Plus, at least several more biosimilar applications will be considered by FDA this year. Soon enough, biosimilars will begin to make a real impact, begin to be noticed and become part of mainstream medical care in the U.S., the major single market for biopharmaceutical products. In the meantime, the more established biosimilar markets in European and other major markets continue to mature, with more biosimilars entering the market and these continuing to incrementally capture increasing market share and displace their reference products. Internationally, the number and use of biogenerics continue to increase, with these products often cited as ‘biosimilars,’ generally manufactured and marketed in lesser- and non-regulated countries, and generally not meeting major market, e.g., U.S. or EU, analytical and clinical testing and manufacturing (GMP) standards for biosimilars or biopharmaceuticals. However, as discussed below, many aspects of the current and future biosimilars market remain uncertain, including many aspects related to product development and manufacturing, including the role of CMOs.

    So far, biosimilars development and approvals has proven to not be as hard as many had originally projected it would be. This includes no recent major market filings having been rejected, no manufacturing halted due to regulatory agency inspection failures, no abandonment of the field by developers or investors, etc. In fact, the field, including the number of companies involved, products in development and their stages of development continue to slowly but steadily increase. This includes the number of biosimilars products in the development pipeline and related numbers of involved manufacturers and marketers. 

    The Biosimilars/Biobetters Pipeline Database online from BioPlan Associates2  now reports over 730 biosimilar products and over 280 companies worldwide substantively involved in biosimilars development, manufacturing and/or marketing.  And biosimilars are slowly advancing in development, as shown in Figure 1. 

    Although the largest portion of products are in preclinical phases, the number of biosimilars in Phase I and II/III trials continues to increase. There are currently at least 35 candidate biosimilars in Phase I trials and 62 in Phase II/III trials with there often being little distinction between Phase II- and III-type biosimilars clinical trials. With little or no related major clinical trial or manufacturing failures reported with biosimilars and few expected, it can be presumed that virtually all of these products now in trials will enter the market eventually.

    In coming years, patent expirations on relevant reference products will increase, making more biosimilars approvable.1 As these patents expire, many more products now in preclinical stages will advance into clinical trials and subsequently enter the market. Anecdotal evidence indicates that a good portion of developers with products currently in preclinical phases are simply waiting to advance their candidate products into clinical trials as relevant patent expirations approach and/or for FDA to issue more regulations and/or give more actually-useful guidance concerning U.S. biosimilar approvals. A good portion of future major biosimilar players may also be waiting for more U.S. and EU regulations and guidance concerning fully interchangeable biosimilars, with these expected to be marketed much like nearly all A-B interchangeable generic drugs, meaning they will simply be manufactured and available for purchase without the costly marketing and promotion associated with an innovator/reference product. In the meantime, developers and manufacturers in developing countries are continuing to develop and launch into the market an increasing number of biogenerics; an increasing number of these manufacturers will seek to advance to full cGMP manufacturing to make their products licensable and marketable in the U.S., EU and other highly-regulated major markets.
     
    CMOs well-suited for biosimilars
    CMOs, anecdotally have reported seeing as much as a 15% increase in the number of projects and revenue from taking-on biosimilars development and manufacturing for clients.1 Beyond this, currently little is actually documented about current and near-term future biosimilar development and manufacturing, including CMO involvement. But it is logical to predict that CMOs are increasingly and significantly involved in biosimilar development and manufacture. In many respects, biosimilars are perfectly suited for CMOs with expertise in cost-efficient manufacturing. Reasons for this include:
    • Biosimilars, compared to innovative biopharmaceuticals, for most developers are not among their companies highest priorities. They do not generally involve high projected revenue. Rather, biosimilars will continue to impact smaller markets, with biosimilars competing with the reference product, and with each other. This tends to be a good reason to outsource biosimilar development and manufacture.
    • CMOs have a history of success in developing and manufacturing products, including about 30% of currently marketed major market biopharmaceutical products being manufactured at some scale by a CMO. There is every reason to presume this frequent use of CMOs will carry over to biosimilars.
    • CMOs generally have much more diverse expertise and equipment than most developer companies, and tend to work efficiently—they simply have to, to remain competitive. CMOs work on many more projects/products using more diverse technologies, and they are more set up for and experienced with flexible and rapid process and product development.
    • Many CMOs have been or are currently working on multiple biosimilars for clients. This includes sometimes working on biosimilar versions of the same reference product for multiple clients. Thus, many CMOs already have more experience with biosimilars than developer companies, including analytical studies and process development.
    • CMO use has been proven cost-effective, and use of CMOs provides increased flexibility for developer companies. With market sizes, the number of competitors, and other aspects related to needed biosimilar manufacturing capacity remaining unknown, the flexibility afforded by use of CMOs, including their ability to rapidly ramp-up manufacturing as needed, makes their use more attractive, if not essential.
    • Associated with their flexibility and high levels of expertise, CMOs, even if not used by developers for product and process development, will increasingly be used as second-source or back-up manufacturing facilities by developer companies that pursue primary product manufacturing in-house. 
    • Single-use systems and other bioprocessing advances are making product development and manufacturing efforts simpler, cheaper and more rapid, including quicker product manufacturing turnover; and advances are continuing to reduce the needed size of bioprocessing hardware, suites and facility footprints. CMOs are particularly well positioned to take advantage of the cost savings, flexibility and other advantages these trends provide.
    Resolving biosimilar manufacturing-related uncertainties
    While there is much anecdotal reporting about developer company and CMO involvement in biosimilars, to date, there have been no actual studies and no information available concerning many of the bioprocessing-related aspects of current and future biosimilars development and manufacturing. Current unknowns include:
    • Types of CMO involvement in biosimilar development and commercial manufacturing expected in the future, e.g., in 5 years. 
    • Why are developers hiring CMOs? Should companies plan for preclinical and early trial support, or for commercial manufacturing?
    • Future manufacturing strategies for commercial biosimilars production by CMOs vs. developers. How should CMOs, and other service providers prepare for biosimilars?
    • General approaches to product manufacturing, such as using single-use or multi-product suites or facilities; will manufacturing be done in new facilities? Will current monoclonal antibody (mAb) manufacturers produce biosimilar mAbs in existing ≥10,000 L bioreactors, perhaps only partially filling for manufacturing runs?
    • Will biosimilar manufacturing be more effective in single-use, stainless steel or a hybrid mix of hardware?  Will adopting continuous manufacturing options, such as perfusion be a viable option?
    • Where will developers have their biosimilars manufactured? Major markets; CMOs current or new facilities? Regional manufacturing where costs are presumed to be lower? Will a portion of major market biosimilars be manufactured by CMOs in countries such as India or China?
    • Will biosimilar be done in modern state-of-the-art operations, or will they attempt to emulate now-legacy reference product manufacturing technologies? So far, current major market developers appear to be manufacturing using modern state-of-the-art technologies. But, given the focus on efficient production, will different expression systems be used? E.g., HEK-293, or switching to E. coli rather than the reference product’s use of CHO.
    To resolve these unknowns regarding biosimilar manufacturing and CMO involvement, BioPlan Associates is expanding its public biosimilar development and manufacturing databases. In addition to its Biosimilars/Biobetter Pipeline Database development pipeline tracking database (www.biosimilarspipeline.com), BioPlan has expanded its free Top 1000 Biopharmaceutical Facilities web site (www.top1000bio.com) to include Top 100 Biosimilar Facilities analysis. As with our BioPlan industry projects, including 30-year trends data for in bioprocessing titers and yields,3,4 biosimilars projects aggregate current biosimilars developments to compile all public data. 
    Because biosimilars manufacturing is plotting uncharted territory in biomanufacturing strategy, we will continue to identify and define the alternative paths to traditional in-house and contract bioprocessing that continues to emerge—especially as they relate to efficient GMP production. The global nature of biomanufacturing also opens a space for manufacturers in developing regions. 

    While the biosimilars industry is not likely to resemble today’s industry, it’s also safe to project that the efficiencies emerging from the most productive and competitive CMOs are likely to play an important role in the future of bioprocessing at all levels. 

    References:
    1. Rader. R.A., Langer, E.S., “Biosimilars Improving Efficiency and Cost for All Biologics,” Contract Pharma, April 2015, p. 28-30.
    2. Rader, R.A., Biosimilars/Biobetters Pipeline Database, BioPlan Associates, online at www.biosimilarspipeline.com.
    3. Rader. R.A., Langer, E.S., “Thirty Years of Upstream Productivity Improvements,” BioProcess International, 14(2), Feb. 2015, p. 10-14.
    4. Rader. R.A., Langer, E.S., “Biopharmaceutical Manufacturing: Historical and Future Trends in Titers, Yields, and  Efficiency in Commercial-Scale Bioprocessing,” BioProcessing J., 13(4), Winter 2014/2015,  p. 47-54.

    Ronald A. Rader is senior director, technical research at BioPlan Associates. Mr. Rader has over 25 years experience as a biotechnology, and pharmaceutical information specialist and publisher, including editor/publisher of Antiviral Agents Bulletin, editor-in-chief of the journal Biopharmaceuticals, and many data resources including Biopharmaceutical Products in the U.S. Market, now in its 12th Ed, and the first biosimilars database.

    Eric S. Langer is president and managing partner at BioPlan Associates, a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing,” and many other industry reports. elanger@bioplanassociates.com; 301-921-5979; www.bioplanassociates.com
    Related Searches
    • Clinical Trials
    • Process Development
    • GMP
    • Clinical Trial
    Suggested For You
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Lonza Appoints Philippe Deecke as CFO Lonza Appoints Philippe Deecke as CFO
    Stelis Biopharma Appoints Mark Womack as CEO Stelis Biopharma Appoints Mark Womack as CEO
    Pfizer Pfizer's 2Q Revenues Up 92%
    Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up
    Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology
    Teva Teva
    Pfizer 1Q Revenues up 45% Driven by COVID Vax Pfizer 1Q Revenues up 45% Driven by COVID Vax
    Catalent Biologics Completes Madison Expansion Catalent Biologics Completes Madison Expansion
    Pfizer Pfizer's 4Q Revenues up 12%
    Financial Report: Roche Financial Report: Roche
    CDMO Stelis Continues Expansion CDMO Stelis Continues Expansion
    Mogene Mogene
    Stelis BioSource Continues Facility Investment Stelis BioSource Continues Facility Investment
    Financial Report: Pfizer Financial Report: Pfizer

    Related Content

    • Breaking News | Collaborations & Alliances | Industry News
      Lakes BioScience Signs Agreement with Cytvia

      Lakes BioScience Signs Agreement with Cytvia

      Initiates the implementation of innovative workflows at Lakes BioScience’s factory in Cumbria.
      09.14.21

    • Breaking News | Promotions & Moves
      Lonza Appoints Philippe Deecke as CFO

      Lonza Appoints Philippe Deecke as CFO

      Deecke joins Lonza Group from Novartis, where he held a succession of senior finance positions.
      08.27.21

    • Breaking News | Industry News | Promotions & Moves
      Stelis Biopharma Appoints Mark Womack as CEO

      Stelis Biopharma Appoints Mark Womack as CEO

      Assumes the role of chief executive with immediate effect and will be stationed at Stelis HQ in Bengaluru, India.
      08.06.21


    • Breaking News | Financial Reports
      Pfizer

      Pfizer's 2Q Revenues Up 92%

      COVID-19 vaccine BNT162b2 contributes $7.8 billion in sales and alliance revenues.
      07.29.21

    • Bio News | Biosimilars | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

      Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

      Partnership to support the development and manufacture of biosimilars for global customers.
      07.29.21

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Regulatory Report: Analytical Procedure Development
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      H.M. Royal Becomes Exclusive OCSiAl Distributor
      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Siemens' Varian Gains FDA IDE Nod for FAST-02 Trial
      Acutus Medical Launches AcQCross Line Extension
      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Past Henkel Exec Christian Chopra Named President of Scotch Porter
      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login